Abstract: The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for blocking corepressor binding to a BCL6 lateral groove, methods for inhibiting BCL6 repression in a mammalian cell, and methods for treating a mammal with cancer, wherein the cancer requires BCL6 repression. The present invention is further directed to polypeptides comprising a portion of the corepressor binding site for BCL6 and related polynucleotides and vectors.
Type:
Grant
Filed:
June 10, 2009
Date of Patent:
July 29, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Methods and compositions are disclosed for rapid functional analysis of gene variants based on analysis of protein-protein and protein-nucleic acid interactions.
Type:
Application
Filed:
January 8, 2014
Publication date:
July 10, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Methods are provided for treating a cancer in a subject comprising administering to the subject an agent which inhibits expression of an HLX gene in the subject, or an agent which inhibits activity of an expression product of the HLX gene, and also for diagnosing a subject as likely to develop a cancer comprising determining whether a stem cell obtained from the subject expresses a HLX gene at a level in excess of predetermined control level. Kits therefor are also provided.
Type:
Application
Filed:
May 3, 2012
Publication date:
July 3, 2014
Applicants:
Dana-Farber Cancer Institute, Inc., Albert Einstein College of Medicine of Yeshiva University
Inventors:
Ulrich G. Steidl, Constantine S. Mitsiades
Abstract: Provided are methods of using humanin and humanin analogs to treat a mammal exhibiting or at risk for insulin resistance, increase insulin sensitivity in a mammal exhibiting or at risk for insulin resistance, treat type-2 diabetes mellitus, metabolic syndrome, and neurodegeneration, treat and prevent myocardial injury, and determine longevity.
Type:
Application
Filed:
February 21, 2014
Publication date:
June 26, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: The present invention is based on the identification of a predominant ligand of CD8+ T cells that are responsible for type 1 diabetes. That ligand is islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP). Several CD8+ T cell-binding peptides from IGRP are identified, including the peptide comprising amino acids 206-214 of the IGRP sequence, which has high avidity to the most prevalent T cell receptor of pathogenic CD8+ T cells in autoimmune diabetes. The invention thus provides oligopeptide and polypeptide compositions comprising YLKTN(A/I/L/V)FL (SEQ ID NO:3), FLWSVFWLI (SEQ ID NO:4), (T/A)YY(G/T)FLNFM (SEQ ID NO:5), LR(L/V)(F/L)(G/N)IDLL (SEQ ID NO:6), KWCANPDWI (SEQ ID NO:7), and SFCKSASIP (SEQ ID NO:8). Also provided are oligopeptide compositions 8-10 amino acids in length and completely homologous with a mammalian IGRP, where the oligopeptide is capable of binding a human MHC class I molecule.
Type:
Grant
Filed:
May 20, 2004
Date of Patent:
June 24, 2014
Assignees:
Albert Einstein College of Medicine of Yeshiva University, University of Virginia Patent Foundation, University Technologies International Inc.
Inventors:
Teresa P. DiLorenzo, Anne M. Evans, Donald F. Hunt, Scott M. Lieberman, Stanley G. Nathenson, Pere Santamaria, Jeffrey Shabanowitz
Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.
Type:
Grant
Filed:
June 9, 2006
Date of Patent:
June 3, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
Seetharama A. Acharya, Belur N. Manjula
Abstract: Methods and apparatus are disclosed for imaging molecular interactions in living cells at high resolution, low light levels and high acquisition speeds.
Type:
Application
Filed:
September 13, 2011
Publication date:
May 29, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: A method of treating a tumor in a subject, or reducing or preventing metastasis of a tumor in a subject, is provided comprising administering to the subject an amount of a bacteria labelled with, or comprising, one or more radionuclides so as to treat the tumor in the subject, or so as to reduce or prevent metastasis of the tumor in the subject. Radiobacteria-containing compositions and pharmaceutical compositions are also provided.
Type:
Application
Filed:
February 3, 2012
Publication date:
May 29, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Methods are provided for treating fibrosis of a tissue, including fibrosis of the liver, using combinations of antagomirs and/or locked nucleic acids. Compositions therefor are also provided.
Type:
Grant
Filed:
December 6, 2012
Date of Patent:
May 20, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Methods and compositions are provided for inhibiting metastasis of a tumor in a subject, or of inhibiting progression of a primary tumor in a subject which requires macrophages for progression.
Type:
Grant
Filed:
April 10, 2013
Date of Patent:
May 6, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Methods of treating a disease in a subject are provided comprising administering to the subject an amount of an agent which reduces, or prevents, interaction of a G?? with a pi 110? effective to treat the disease. Methods are also provided for identifying an inhibitor of interaction between a G?? and a ?110?. Compositions are provided comprising a peptide comprising amino acid residues having the KAAEIASSDSANVSSRGGKKFLPV (SEQ ID NO:6).
Type:
Application
Filed:
June 12, 2012
Publication date:
April 24, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Provided are peptides or mimetics that block corepressor binding to a BCL6 lateral groove. Also provided are methods or blocking corepressor binding to the BCL6 lateral groove. Additionally, methods of inhibiting BCL6 repression in a mammalian cell, and methods of treating a mammal with cancer are provided.
Type:
Grant
Filed:
February 23, 2011
Date of Patent:
April 22, 2014
Assignees:
Albert Einstein School of Medicine of Yeshiva University, Mount Sinai School of Medicine
Abstract: This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the ?641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
April 22, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins having at least two specific chemical modifications. PEGylated versions of these hemoglobins are also provided, as are certain tetraPEGylated and diPEGylated hemoglobins. Methods of modifying a hemoglobin are additionally provided, as are methods of making a hemoglobin. Pharmaceutical compositions and blood substitutes using these hemoglobins are further provided, as are methods of treating a subject using these pharmaceutical compositions and blood substitutes.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
April 15, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
Seetharama A. Acharya, Belur N. Manjula
Abstract: The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders.
Type:
Application
Filed:
March 18, 2013
Publication date:
March 27, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
George J. Christ, Kelvin Davies, Arnold Melman
Abstract: The application discloses ketoconazole derivatives that are antagonists of the human pregnane X receptor (PXR), methods of preparing the derivatives, uses of the derivatives with drug therapy, and methods of inhibiting tumor cell proliferation and multidrug resistance using inhibitors of PXR.
Type:
Grant
Filed:
January 27, 2009
Date of Patent:
March 11, 2014
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: Methods are provided of treating or preventing diabetes in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog. Methods are also provided of increasing insulin secretion in a subject comprising administering to the subject an amount of oxytocin or an oxytocin analog.
Type:
Application
Filed:
August 26, 2013
Publication date:
March 6, 2014
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.
Type:
Application
Filed:
February 24, 2012
Publication date:
March 6, 2014
Applicants:
Massachusetts Institute of Technology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University
Inventors:
Frank B. Gertler, Christopher Boyce Burge, Irina M. Shapiro, Wu Albert Cheng, John S. Condeelis, Maja H. Oktay
Abstract: Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena.
Type:
Application
Filed:
November 7, 2013
Publication date:
February 27, 2014
Applicants:
Albert Einstein College of Medicine of Yeshiva University, IFO-Regina Elena Cancer Institute, Massachusetts Institute of Technology
Inventors:
John S. Condeelis, Sumanta Goswami, Frank Gertler, Paola Nistico